Accordingly, we inspected whether AML patients with low and high levels of biomarkers as NDUFA6, SDHA, CYB5A, SLC25A12, ETFB and CPT1A have differential leukemic burden in their peripheral blood and bone marrow biospecimens. This evidence concerns the gene SLC25A12 and acute myeloid leukemia.